BlossomHill Therapeutics, Inc. Tech Stack

Small molecule drug discovery for oncology and autoimmune disorders

Biotechnology Research San Diego, California 51–200 employees Founded 2020 Privately Held

BlossomHill is a San Diego-based drug discovery company founded in 2020, focused on small molecule development in oncology and autoimmune space. The tech stack (NONMEM, Monolix, Phoenix WinNonlin, LC-MS, GC-MS, ICP-MS) reflects classical pharmacokinetic/pharmacodynamic modeling and analytical chemistry workflows — standard for early-stage biotech. Active hiring in finance and accounting leadership, combined with projects around IPO preparation, SEC filing, Sarbanes-Oxley compliance, and internal control systems, signals the company is moving toward public markets and scaling infrastructure to match regulatory demands.

Tech Stack 11 technologies

Core StackNONMEM Monolix Phoenix WinNonlin R LC-MS GC-MS ICP-MS FT-IR PLM Excel PowerPoint

What BlossomHill Therapeutics, Inc. Is Building

◆Challenges

Vendor oversight inefficiencies
Optimizing benefit-risk profile
Improving drug development efficiency
Timely completion of deliverables
Oot/oos investigations
Preparing for potential ipo
Scaling accounting organization for growth
Ensuring sarbanes-oxley compliance
Managing vendor budgets
Risk mitigation in clinical trials

▲Active Projects

Development of templates, style guidelines, and sops for clinical documentation
Manage external writing vendors for medical writing book of work
Data capture tool implementation
Submission readiness preparation
Midd strategy development
Clinical pharmacology study design
Population pk/pd modeling
Ipo preparation and sec filing
Scaling accounting organization for growth
Implementing internal control system

Hiring Activity

Accelerating7 roles · 4 in 30d

Department

Finance

Healthcare

Research

Data

Seniority

Director

Senior

Notable leadership hires: Accounting Director, Finance Director

Company intelligence

Find more companies like BlossomHill Therapeutics, Inc. by tech stack, pain points and active projects

Get started free

About BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics develops small molecule drugs targeting unmet needs in oncology and autoimmune disorders. Founded by drug design scientist J. Jean Cui, Ph.D., and biotech veteran Y. Peter Li, Ph.D., M.B.A., the company operates at 51–200 employees in San Diego. Current project focus spans clinical pharmacology study design, population PK/PD modeling, clinical documentation standards, and submission readiness — typical milestones for programs advancing toward regulatory filing. The organization is simultaneously scaling accounting and finance functions while preparing for potential public offering.

HeadquartersSan Diego, California

Company Size51–200 employees

Founded2020

Hiring MarketsUnited States

Frequently Asked Questions

What is BlossomHill Therapeutics working on?

Small molecule drug discovery in oncology and autoimmune disorders. Active projects include clinical pharmacology study design, population PK/PD modeling, clinical documentation templates, and IPO and SEC filing preparation.

Where is BlossomHill Therapeutics headquartered?

San Diego, California. Founded in 2020, the company operates as a privately held biotech firm with 51–200 employees in the United States.

What tech stack does BlossomHill use?

Pharmacokinetic and analytical chemistry tools: NONMEM, Monolix, Phoenix WinNonlin for PK/PD modeling; LC-MS, GC-MS, ICP-MS for mass spectrometry; PLM for document management; and standard office tools (Excel, PowerPoint, R).